Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-099254
Filing Date
2025-07-28
Accepted
2025-07-28 17:15:12
Documents
1
Period of Report
2025-07-25

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 21942
  Complete submission text file 0000950170-25-099254.txt   23380
Mailing Address C/O DYAX CORP. 55 NETWORK DRIVE BURLINGTON MA 01803
Business Address
Ashe Andrew D. (Reporting) CIK: 0001573163 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40489 | Film No.: 251156628

Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Issuer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)